Overview of KAHF Technology: A Target-Centric Therapeutic Ecosystem
A Solution for Early Stage Cancer and Metastatic Patients
Lead Program: Pancreatic Ductal Adenocarcinoma (PDAC)
KAHF Biotech is pioneering a breakthrough approach to treating pancreatic and other solid tumors by targeting the KAHF receptor, a novel driver of cancer progression and metastasis. In preclinical studies (GEMM and Orthotopic Models), KAHF receptor inhibition suppressed metastasis in early-stage PDAC, eliminated micro-metastatic tumor cells, and sensitized resistant tumors to standard therapies.
We are advancing a first-in-class therapeutic antibody (Anti-KAHF mAb) designed to block this receptor and disrupt the molecular pathways driving tumor invasion, progression, metastasis, and immune evasion. Our goal is to deliver a transformative new treatment for patients with pancreatic and other aggressive cancers.
Expanding Horizons: KAHF Biotech Pursuing Next-Generation Therapeutic Platforms
KAHF Biotech is pioneering a target-centric approach to oncology, building therapeutic franchises around high-value cancer targets and matching each target with the modality best suited to the biology and disease indication. Across monoclonal antibodies, ADCs, T-cell and NK-cell engagers, CAR-T/CAR-NK therapies, Antibody–Oligonucleotide Conjugates (AOCs), Degrader Antibody Conjugates (DACs), and other targeted platforms, KAHF develops disease-specific therapeutic strategies designed around tumor biology, target expression, and clinical need. This approach enables a single target-centric foundation to generate multiple differentiated products across selected cancer types and stages of disease.